IntelGenx Receives Amended DEL License to Conduct Third-Party Testing
17 Maio 2023 - 9:00AM
IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or
"IntelGenx") a leading drug delivery company, is pleased to
announce that it has received an amended Drug Establishment License
(“DEL”) from Health Canada, allowing the Company to conduct
third-party testing.
Analytical testing of finished products and
intermediates is a significantly underserved market, which
IntelGenx has decided to tap into. The Company views this as an
attractive opportunity for short-term revenue generation. The
amended DEL license could be of particular importance due to
IntelGenx's possession of a controlled substance license. This
allows IntelGenx to access a broader market for testing services,
further increasing its market penetration and revenue
opportunities.
"By expanding our core CDMO business to include
a third-party testing services offering, our aim is to offer
‘one-stop-shopping’ to our development partners,” said Dwight
Gorham IntelGenx’s CEO. “IntelGenx's testing laboratory boasts
exceptional efficiency and is currently operating at under
capacity. This surplus in capacity allows us to seize the
opportunity to generate revenue from third-party testing without
any additional investment. While testing services will not be our
primary focus, the added revenue will be welcomed, while at the
same time, help foster business relationships with key players in
the Canadian market.”
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm®, DisinteQ™, VetaFilm® and transdermal
VevaDerm™, allow for next generation pharmaceutical products that
address unmet medical needs. IntelGenx’s innovative product
pipeline offers significant benefits to patients and physicians for
many therapeutic conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward-Looking Information and
Statements
This document may contain forward-looking
information about IntelGenx's operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx's plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx's actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx's annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations(647)
872-4849stephen@kilmerlucas.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx Corp.(514)
331-7440 ext 203andre@intelgenx.com
Intelgenx Technologies (TSX:IGX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Intelgenx Technologies (TSX:IGX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024